Bayer HealthCare Pharmaceuticals Inc., of Whippany, N.J., said the FDA has accepted the filing of a supplemental biologics license application for Betaconnect (proposed name), another delivery option for Betaseron (interferon beta-1b), a treatment for relapsing-remitting multiple sclerosis.